Biomarin

BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
Endpoints
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link:
BioMarin, Spark, raising the stakes for hemophilia
BioMarin, Spark, raising the stakes for hemophilia
BioPharma Dive
Biomarin
Spark Therapeutics
hemophilia
BMN 270
SPK-9001
gene therapy
Flag link:
BioMarin CEO says 'the system will have to determine' the worth of its new $702,000 drug
BioMarin CEO says 'the system will have to determine' the worth of its new $702,000 drug
CNBC
Biomarin
Brineura
drug pricing
Batten disease
Flag link:
4 Drug Stocks With Big News Coming in April
4 Drug Stocks With Big News Coming in April
Motley Fool
Neurocrine
Incyte
Eli Lilly
Biomarin
Ingrezza
baricitinib
Brineura
Flag link:
BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster
BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster
Motley Fool
Biomarin
earnings
Vimizim
Kuvan
Naglazyme
Flag link:
BioMarin sues to stop generic version of its $90K-a-year drug
BioMarin sues to stop generic version of its $90K-a-year drug
Bizjournals.com
Biomarin
generics
Kuvan
Dr Reddy's
Flag link:
Biotech Investing: 3 Bold Predictions for 2017
Biotech Investing: 3 Bold Predictions for 2017
Motley Fool
biotech
Incyte
Biogen
Biomarin
Gilead Sciences
Illumina
Flag link:
7 of the Most Shocking Biotech Pipeline Blowups of 2016
7 of the Most Shocking Biotech Pipeline Blowups of 2016
Motley Fool
biotech
Alnylam
revusiran
Clovis Oncology
rociletinib
Celldex Therapeutics
Rintega
Eli Lilly
solanezumab
Novavax
RSV-F
Arrowhead
ARC-520
ARC-521
ARC-AAT
Biomarin
drisapersen
Flag link:
BioMarin’s Disappointing 3Q16 Earnings
BioMarin’s Disappointing 3Q16 Earnings
Market Realist
Biomarin
earnings
Flag link:
Sarepta Therapeutics' Greatest Threat: Anthem?
Sarepta Therapeutics' Greatest Threat: Anthem?
Motley Fool
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 5
Biomarin
Anthem
Flag link:
FDA’s controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin
FDA’s controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin
Endpoints
FDA
eteplirsen
Duchenne Muscular Dystrophy
Biomarin
Sarepta Therapeutics
Flag link:
3 Biotechs Most Likely to Be Acquired
3 Biotechs Most Likely to Be Acquired
Motley Fool
biotech
M&A
Incyte
Biomarin
Biogen
Flag link:
After Sarepta win, BioMarin appeals DMD patent ruling
After Sarepta win, BioMarin appeals DMD patent ruling
BioPharma Dive
Sarepta Therapeutics
Biomarin
patents
Duchenne Muscular Dystrophy
eteplirsen
Kyndrisa
Flag link:
BioMarin hits snag with latest rare disease drug
BioMarin hits snag with latest rare disease drug
BioPharma Dive
Biomarin
Brineura
FDA
CLN2 disease
Flag link:
3 Biotech Stocks Could Be the Next Big Takeover Targets
3 Biotech Stocks Could Be the Next Big Takeover Targets
24/7 Wall St
biotech
M&A
Biomarin
Incyte
Tesaro
Flag link:
4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss
4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss
Barron's
biotech
M&A
Gilead Sciences
Sanofi
Medivation
Incyte
Biomarin
Tesaro
Seattle Genetics
Flag link:
Sarepta: The Competition Is At The Gate
Sarepta: The Competition Is At The Gate
Seeking Alpha
Sarepta Therapeutics
eteplirsen
Biomarin
Summit Therapeutics
PTC Therapeutics
Duchenne Muscular Dystrophy
Flag link:
Why BioMarin's Shares Tumbled 11% in June
Why BioMarin's Shares Tumbled 11% in June
Motley Fool
Biomarin
M&A
Duchenne Muscular Dystrophy
Sanofi
drisapersen
Kyndrisa
Flag link:
BioMarin Pharmaceutical shares rise after possible takeover from Roche
BioMarin Pharmaceutical shares rise after possible takeover from Roche
CNBC
Biomarin
M&A
Roche
Flag link:
3 Plausible Buyout Scenarios Within Biotech
3 Plausible Buyout Scenarios Within Biotech
Seeking Alpha
biotech
Acadia
AstraZeneca
Allergan
Biogen
Teva Pharmaceutical
Biomarin
Incyte
Ironwood
Medivation
Pfizer
Relypsa
Synergy Pharmaceuticals
M&A
Flag link: